This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luzio, S. D. Articles by Owens, D. R. Search for Related Content PubMed PubMed Citation Articles by Luzio, S. D. Articles by Owens, D. R.

Effects of Timing of Administration and Meal Composition on the Pharmacokinetic and Pharmacodynamic Characteristics of the Short-Acting Oral Hypoglycemic Agent Nateglinide in Healthy Subjects

Diabetes Research Unit (S.D.L., D.R.O.), Llandough Hospital, Penarth, South Glam, CF64 2XX; and Ajinomoto Pharmaceuticals Europe Ltd. (D.M.A.), Redhill, Surrey RH1 1RX, United Kingdom

Address all correspondence and requests for reprints to: Dr. S. D. Luzio, Diabetes Research Unit, Llandough Hospital, Penlan Road, Penarth, South Glam, CF64 2XX, United Kingdom. E-mail: luzio{at}cf.ac.uk

Abstract

These studies examined the influence of timing of administration of nateglinide on the glucose profile and ß-cell secretory response to a standardized test meal and the effect of meal composition on the pharmacokinetic and pharmacodynamic profile. In study 1, nateglinide (60 mg) or placebo was given orally at -10, -1, or +10 min to healthy subjects (n = 12), in relation to a standardized test meal (500 kcal) that commenced at 0 min. In study 2, also in healthy subjects (n = 12), a single oral dose (60 mg) of nateglinide was given either 10 min before or 10 min after the start of each of three different test meals (i.e. high in carbohydrate, fat, or protein). In both studies, the postmeal observation period was a minimum of 240 min. In the first study premeal (-10,-1 min), administration of nateglinide led to earlier and higher peak plasma nateglinide concentrations, compared with postprandial dosing (+10 min). A significantly lower maximum postprandial glucose concentration was seen with preprandial dosing compared with either placebo (P < 0.01) or nateglinide given postprandially (P < 0.01). The impact on the glucose profile was consistent with the enhanced insulin profiles after nateglinide, resulting in higher peak plasma insulin concentrations compared with placebo (P < 0.01). Study 2 confirmed the greater impact of pre- vs. postprandial dosing on the glucose and insulin profiles, irrespective of meal type. Nateglinide administration, before a meal, resulted in a more rapid rise and higher peak nateglinide plasma concentrations, irrespective of meal composition. Preprandial administration of nateglinide was more effective in reducing prandial glucose excursions, compared with postmeal dosing (+10 min), a consequence of the earlier insulin response.

This article has been cited by other articles:

				M. Scarsi, M. Podvinec, A. Roth, H. Hug, S. Kersten, H. Albrecht, T. Schwede, U. A. Meyer, and C. Rucker Sulfonylureas and Glinides Exhibit Peroxisome Proliferator-Activated Receptor {gamma} Activity: A Combined Virtual Screening and Biological Assay Approach Mol. Pharmacol., February 1, 2007; 71(2): 398 - 406. [Abstract] [Full Text] [PDF]

				M. F. Carroll, A. Gutierrez, M. Castro, D. Tsewang, and D. S. Schade Targeting Postprandial Hyperglycemia: A Comparative Study of Insulinotropic Agents in Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5248 - 5254. [Abstract] [Full Text] [PDF]